NextFin News - Chiesi Farmaceutici SpA has reached an agreement to acquire KalVista Pharmaceuticals Inc. for approximately $1.9 billion, marking a significant expansion for the Italian family-owned drugmaker into the rare disease market. The deal, announced Wednesday, centers on KalVista’s recently approved oral treatment for hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition characterized by severe swelling.
Under the terms of the agreement, Chiesi will pay $28 per share in cash for the Nasdaq-listed biotech firm. This represents a substantial premium over KalVista’s recent trading levels, valuing the company’s equity at nearly $2 billion. The acquisition follows the U.S. Food and Drug Administration’s recent approval of KalVista’s lead asset, Ekterly (sebetralstat), which became the first oral on-demand therapy for HAE attacks. Previously, patients suffering from the condition were forced to rely on injectable or intravenous treatments, which often delayed care during acute episodes.
The transaction is a strategic pivot for Chiesi, which has been aggressively diversifying its portfolio beyond its traditional respiratory business. By absorbing KalVista, Chiesi gains a commercial-ready product in a high-value niche. Hereditary angioedema affects roughly 1 in 50,000 people globally, and the market for HAE therapies has become increasingly competitive as firms seek to replace cumbersome injections with more patient-friendly oral formulations. Chiesi’s global distribution network is expected to accelerate the rollout of Ekterly in Europe and other international markets where the drug is still undergoing regulatory review.
Market reaction to the deal has been largely positive, though some analysts suggest the $1.9 billion price tag reflects a "perfection" scenario. "Chiesi is paying a significant scarcity premium for a de-risked asset," noted Marcus Thorne, a senior healthcare analyst at Alpine Capital. Thorne, who has historically maintained a cautious stance on mid-cap biotech valuations, emphasized that while the FDA approval removes clinical risk, the commercial execution remains a hurdle. His view is not yet the consensus among sell-side firms, many of whom believe the convenience of an oral pill will allow KalVista to rapidly seize market share from established players like Takeda Pharmaceutical Co.
The deal also highlights a broader trend of European pharmaceutical giants hunting for U.S. biotech assets to bolster their pipelines. For Chiesi, this is its largest acquisition since the $1.48 billion purchase of Amryt Pharma in 2023. The company has signaled that it will continue to use its private status and strong cash flow to pursue "bolt-on" acquisitions that fit its rare disease and specialty care focus. The transaction is expected to close in the second half of 2026, subject to customary closing conditions and regulatory approvals from U.S. and European authorities.
However, the path to market dominance is not without obstacles. Competitors are already working on next-generation prophylactic treatments that could reduce the frequency of attacks to near zero, potentially diminishing the need for on-demand therapies like Ekterly. Furthermore, the pricing of rare disease drugs remains under intense scrutiny from U.S. President Trump’s administration, which has continued to push for transparency in pharmaceutical negotiations. Chiesi will need to navigate a complex reimbursement landscape to ensure that the $1.9 billion investment yields the expected returns in an era of heightened cost-containment.
Explore more exclusive insights at nextfin.ai.
